What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

A twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Gilead’s HIV treatment trials involving GS-1720 and GS-4182 have been put on clinical hold by the Food and Drug Administration.

Tens of thousands of deaths and new HIV infections will be the direct result of Donald Trump’s abandonment of PEPFAR and ...

Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...

Kim Canady was only nine years old in 1996 when she faced the unimaginable loss of losing both her parents in the same year. At the time, she didn’t know her parents suffered HIV-related complications ...

Discover how young healthcare innovators from Durban are transforming clinical trials and community health, earning accolades ...